<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38173949</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Differences Between Patients With Chronic Epipharyngitis With and Without Previous COVID-19 Infection.</ArticleTitle><Pagination><StartPage>e51543</StartPage><MedlinePgn>e51543</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e51543</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.51543</ELocationID><Abstract><AbstractText>Objective Epipharyngeal abrasive therapy (EAT) is effective in patients with chronic epipharyngitis who previously had coronavirus disease 2019 (COVID-19). The study aimed to evaluate differences between patients with chronic epipharyngitis with (long COVID) or without a history of COVID-19 (non-long COVID). Methods This is a retrospective study based on the analysis of medical records of patients who visited the Mogitate ENT Clinic in Kawasaki, Japan,&#xa0;for six months from March 2022. Results Patients with long COVID&#xa0;were significantly younger (p=0.018). Fatigue&#xa0;and brain fog&#xa0;were prevalent in patients with long COVID, whereas throat discomfort,&#xa0;postnasal drip,&#xa0;and sputum&#xa0;were more common in those with non-long COVID. Epipharyngeal endoscopic findings in patients with long COVID showed significantly higher scores (p&lt;0.001) compared with patients with non-long COVID. Conclusions The primary differences between patients with long COVID and non-long COVID were age, symptoms, and severity scores of endoscopic findings. The EAT should be aggressively implemented in patients with chronic epipharyngitis with or without COVID-19 infection, as there is no reason not to treat a patient with a condition caused by COVID-19 infection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, Mogitate et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mogitate</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Otolaryngology, Mogitate ENT Clinic, Kawasaki, JPN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">endoscopy</Keyword><Keyword MajorTopicYN="N">infectious disease</Keyword><Keyword MajorTopicYN="N">naso-pharynx</Keyword><Keyword MajorTopicYN="N">outcome</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38173949</ArticleId><ArticleId IdType="pmc">PMC10761321</ArticleId><ArticleId IdType="doi">10.7759/cureus.51543</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). Fact sheets: post COVID-19 condition (long COVID)  [
Jan;
2023 
]. 2022. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</Citation></Reference><Reference><Citation>Epipharyngeal abrasive therapy (EAT) has potential as a novel method for long COVID treatment. Imai K, Yamano T, Nishi S, et al. Viruses. 2022;14:907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147901</ArticleId><ArticleId IdType="pubmed">35632649</ArticleId></ArticleIdList></Reference><Reference><Citation>Effect of epipharyngeal abrasive therapy on long COVID with chronic epipharyngitis. Ito H. SJO. 2022;8:939&#x2013;946.</Citation></Reference><Reference><Citation>COVID-19 and chronic fatigue syndrome: an endocrine perspective. Bansal R, Gubbi S, Koch CA. J Clin Transl Endocrinol. 2022;27:100284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8641402</ArticleId><ArticleId IdType="pubmed">34877261</ArticleId></ArticleIdList></Reference><Reference><Citation>A prospective study on the efficacy of epipharyngeal abrasive therapy Report 1 (in Japanese) Harabuchi Y. https://www.jstage.jst.go.jp/article/stomatopharyngology/35/3/35_303/_pdf/-char/ja Stomato Pharyngol. 2022;35:303.</Citation></Reference><Reference><Citation>Outcome of an outpatient specialty clinic for chronic epipharyngitis. Mogitate M, Sasaki Y, Komiyama A. Auris Nasus Larynx. 2021;48:451&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">33067050</ArticleId></ArticleIdList></Reference><Reference><Citation>Possible mechanisms underlying epipharyngeal abrasive therapy (EAT) with ZnCl2 solution for the treatment of autoimmune diseases and functional somatic syndrome. Hotta O, Inoue CN, Tanaka A, Ieiri N. J Antivir Antiretrovir. 2017;9:81&#x2013;86.</Citation></Reference><Reference><Citation>Visualizing the data: information on COVID-19 infections.  [
May;
2023 
]. 2023. https://covid19.mhlw.go.jp https://covid19.mhlw.go.jp</Citation></Reference><Reference><Citation>Epipharyngeal abrasive therapy down-regulates the expression of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Nishi K, Yoshimoto S, Nishi S, et al. In Vivo. 2022;36:371&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8765169</ArticleId><ArticleId IdType="pubmed">34972736</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. Ahn JH, Kim J, Hong SP, et al. J Clin Invest. 2021;131:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245175</ArticleId><ArticleId IdType="pubmed">34003804</ArticleId></ArticleIdList></Reference><Reference><Citation>Prolonged and late-onset symptoms of coronavirus disease 2019. Miyazato Y, Morioka S, Tsuzuki S, et al. Open Forum Infect Dis. 2020;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>Autonomic nervous system regulation effects of epipharyngeal abrasive therapy for myalgic encephalomyelitis/chronic fatigue syndrome associated with chronic epipharyngitis. Hirobumi I. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9840732</ArticleId><ArticleId IdType="pubmed">36655156</ArticleId></ArticleIdList></Reference><Reference><Citation>Effectiveness of epipharyngeal abrasive therapy on chronic epipharyngitis and the exhaled nitric oxide levels. Mogitate M. Intern Med. 2023;62:1139&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10183283</ArticleId><ArticleId IdType="pubmed">36130898</ArticleId></ArticleIdList></Reference><Reference><Citation>A potential novel treatment for chronic cough in long COVIDpatients: clearance of epipharyngeal residual SARS-CoV-2 Spike RNA by epipharyngeal abrasive therapy. Nishi K, Yoshimoto S, Tanaka T, Kimura S, Shinchi Y, Yamano T. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9815934</ArticleId><ArticleId IdType="pubmed">36618501</ArticleId></ArticleIdList></Reference><Reference><Citation>The discovery of nasopharyngitis and its influence on general diseases. Horiguchi S. https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=PASCAL7650231038 Acta Oto-Laryngol Suppl. 1975;329:1&#x2013;120.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>